The Liquid Biopsy Summit 2018

Meet with Q2 Solutions at the 2018 Liquid Biopsy Summit and learn how our genomic experts can help you uncover invaluable insights from your laboratory data and liquid biopsy studies

San Francisco, CA | June 21, 2018 - June 22, 2018 | 09:00 - 18:00 Add to Calendar
Stay Informed Schedule a Meeting

About This Event

Q2 Solutions’ precision medicine solutions cover the entire drug development continuum. Our genomics capabilities can help you identify predictive biomarkers, thereby reducing development costs and timelines. We can partner with you in demonstrating the safety and efficacy of your therapeutic products by identifying patients who may respond most appropriately to a particular therapeutic.

Through carefully orchestrated analyses, Q2 Solutions works with you to choose platforms and assays that will distinctly fit your liquid biopsy study needs, and then use them to deliver valuable, informative data. We offer tailored solutions for challenging specimens such as whole blood and FFPE tissues, as well as nucleic acid isolation and data analysis services.

Whether you need targeted or comprehensive capabilities in preclinical, clinical trials, companion diagnostic and therapeutic co-development, we can help you better understand the biology of disease from biomarker discovery through to commercialization, and deliver the right treatment at the right time and the right dose to the right patient to leverage your liquid biopsy efforts.

Schedule a meeting with Q2 Solutions at this year’s Liquid Biopsy Summit to learn how partnering with our experts can help you determine the best methods to obtain the data you need to overcome your liquid biopsy study challenges, solve complex biological problems, realize efficiencies, mitigate risks and improve your clinical outcomes.

We look forward to meeting you in San Francisco.

Related Services:

Register for Event

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Companion Diagnostic Development: Current trends and recommendations

Read More